SCHEMBL5365065

SCHEMBL5365065

O=C(O)c1cccc(NC(=S)N/N=C\c2cccc(-c3ccc(Cl)cc3)c2O)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.65
GAA P10253 8/20 0.65
KDM4E B2RXH2 8/20 0.65
SMN1; SMN2 Q16637 8/20 0.65
ALDH1A1 P00352 11/20 0.55
RAB9A P51151 9/20 0.55
NPC1 O15118 8/20 0.55
KMT2A Q03164 7/20 0.55
MEN1 O00255 6/20 0.55
L3MBTL1 Q9Y468 2/20 0.53
MITF O75030 1/20 0.53
PKM P14618 2/20 0.52
MAPK1 P28482 2/20 0.52
STAT3 P40763 1/20 0.52
STAT1 P42224 1/20 0.52
POLB P06746 4/20 0.52
THRB P10828 2/20 0.52
HPGD P15428 2/20 0.52
LMNA P02545 3/20 0.51
TP53 P04637 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5365068 1.00 MAPT (0.65) MAPTGAAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5364925 0.91 MAPT (0.64) MAPTGAAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5364928 0.91 MAPT (0.64) MAPTGAAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5363281 0.87 MAPT (0.64) MAPTGAAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5363279 0.87 MAPT (0.64) MAPTGAAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5357158 0.87 GAA (0.66) MAPTGAAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5357150 0.87 GAA (0.66) MAPTGAAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5358192 0.84 MAPT (0.64) MAPTGAAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5358196 0.84 MAPT (0.64) MAPTGAAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5357695 0.83 GAA (0.69) MAPTGAAKDM4ESMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US claimed
US-7241783-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-07-10 US disclosed
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP disclosed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US disclosed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP disclosed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058990-A1 Thrombopoietin mimetics MPL, THPO, TEK MAPT 4635/4885GAA 3120/4885KDM4E 3460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.